RayBiotech, Inc.

3607 Parkway Lane suite 200
Norcross,GA 30092
Tel: 770-729-2992, 1-888-494-8555
Fax: 770-206-2393
Website: www.raybiotech.com
Email: info@raybiotech.com

Certificate of Analysis and Data Sheet

Influenza A (A/Panama/2007/99) (H3N2)

Catalog No.
MD-14-0303P

Description

Influenza Virus Type A (H3N2), Strain A/Panama/2007/99

Preparation

Purification: >90% pure (SDS-PAGE). Ultracentrifugation using 10–40% sucrose gradient

Source: Allantoic fluid of 10 day old embryonated eggs inoculated with influenza A virus
Strain: A/Panama/2007/99

Formulation

Format: Purified, Liquid

Buffer: 0.05M Tris-HCl, pH 8.0 containing 0.1M Sodium chloride, 5mM EDTA

Preservatives: 0.1% Sodium azide, 0.005% Thimerosal

Approx Protein Concentration: 1.3mg/ml (BCA method)

Application

Serological studies of influenza A virus, immunogen for antibody production. Has been tested with MAb to Influenza A (Catalog #MD-05-0306) in ELISA. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.

Inactivation

Thimerosal and beta propiolactone treatment

Storage

Store at -20°C. Avoid multiple freeze/thaw cycles.

RayBiotech, Inc.

3607 Parkway Lane suite 200
Norcross,GA 30092
Tel: 770-729-2992, 1-888-494-8555
Fax: 770-206-2393
Website: www.raybiotech.com
Email: info@raybiotech.com

Warnings

This product contains sodium azide, which has been classified as Xn (Harmful), in European Directive 67/548/EEC in the concentration range of 0.1–1.0%. When disposing of this reagent through lead or copper plumbing, flush with copious volumes of water to prevent azide build-up in drains.

This product has been treated in a manner consistent with methods of inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are required when handling this product.

References

Alarcon, JB., et al., (2007), “Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines”, Clinical and Vaccine Immunology, 14(4): 375-381